Metsera
NY - New YorkBiotechnology
Focus: Metsera is a private biotechnology company focused on obesity therapies using peptide and antibody modalities. The company is in early-to-mid stage development with a pipeline concentrated in metabolic diseases.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PRIVATE
Open Jobs
0
About Metsera
AI assessmentNot HiringNo open roles listed right now. Follow Metsera to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Ad
Obesity and OverweightClinical Trials (1)
NCT06857617This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity
Phase 1/2Help build intelligence for Metsera
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.